EKSPRESI IMUNOHISTOKIMIA PZIP7 PADA INVASIVE BREAST CARCINOMA UNTUK MERAMALKAN AGRESIVITAS TUMOR DAN RESISTENSI KEMOTERAPI
IMMUNOHISTOCHEMICAL EXPRESSION OF PZIP7 IN INVASIVE BREAST CARCINOMA TO PREDICT TUMOR AGGRESSIVENESS AND CHEMOTHERAPY RESISTANCE
Abstract
Invasive breast carcinoma (IBC) bersifat herediter dan paparan estrogen jangka panjang adalah faktor risikonya. Subtipe molekuler IBC dibagi menjadi luminal A, luminal B, HER2-positif, dan triple negatif breast cancer (TNBC). Subtipe molekuler adalah dasar bagi pemberian targeting dan personalized therapy. Resistensi dapat muncul dalam terapi kanker payudara. Untuk menilai resistensi sel-sel kanker payudara setelah pemberian terapi, American Joint Committee on Cancer (AJCC) ke-8 merekomendasikan penggunaan metode Residual Cancer Burden (RCB). Zink berfungsi untuk menstabilkan struktur global p53, selain itu gangguan pada homeostasis zink yang diperantarai oleh transporter terbukti menyebabkan proliferasi sel-sel kanker. Salah satu transporter yang berperan dalam meningkatkan konsentrasi zink di sitoplasma adalah ZIP7. pZIP7 adalah ZIP7 yang telah teraktivasi dan terfosforilasi. Penelitian ini dilakukan dengan pendekatan cross sectional dimulai bulan Juni 2025 sampai Februari 2026 (n=64) pada sediaan histopatologi dengan pulasan hematoxylin-eosin (HE), sediaan imunohistokimia subtipe molekuler IBC dan telah mendapatkan kemoterapi neoadjuvant. Pada penelitian ini IBC paling banyak dijumpai pada kelompok usia 40-49 tahun, subtipe histopatologi IBC NST, subtipe molekuler tipe luminal, dan Nottingham grading system grade 2, ypT3 dan ypN0. RCB class terbanyak adalah class II. Ekspresi imunohistokimia pZIP7 paling banyak dijumpai pada ekspresi imunohistokimia positif di sitoplasma sel-sel tumor dan tidak didapatkan hubungan yang signifikan antara ekspresi pZIP7 dan RCB (p-value: 0.371). Kesimpulan: Ekspresi imunohistokimia pZIP7 belum dapat meramalkan agresivitas dan resistensi terhadap kemoterapi neoadjuvan.
References
Lester SC. Robbins and Cotrans. Basic Pathology 10th ed. Philadelphia: Elsevier. 2021. p.1046-50.
Senkus E, Kyriades SO, Zackrisson S, Penault-Llorca F, Poortmans P, Cardoso F, et al. Clinical Practice Guidelines Primary Breast Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up clinical practice guidelines. ESMO Updat Clin Pract Guidel. 2015;26(Supplement 5): v8-v20. doi:10.1093/annonc/mdv298
Lee S young, Yoo T kyung, Lee SB, Kim J, Chung IY, Ko BS, et al. Prognostic value of residual cancer burden after neoadjuvant chemotherapy in breast cancer: a comprehensive subtype-specific analysis American Joint Committee on Cancer. Published online 2025:1-11. p.1-9
Fitzgibbons PL and Connolly JL. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. College of American Pathologist. 2023;(March). p. 1-19.
Carvalho E, Canberk S, Schmitt F, Vale N. Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies. Cancers (Basel). 2025;17(7). p.1102. Published 2025 Mar 25. doi:10.3390/cancers17071102
Allison KH, Ellis IO, Penault-Llorca F, Salomon AV, Masuda S, Tsuda H, et al. Invasive breast carcinoma: General Overview. In: WHO Classification of Tumour Editorial Board. Breast tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed.; vol. 2). https://publications.iarc.fr/581
Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel). 2021;13(17).p. 5. Published 2021 Sep 3. doi:10.3390/cancers13174455
Kambe T, Tsuji T, Hashimoto A, Itsumura N. The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in Zinc Homeostasis and Metabolism. Physiol Rev. 2015;95(3). p.749-784. doi:10.1152/physrev.00035.2014
Chen R, Yang Y, Miao X, Qin Z, Ni C. Zinc dyshomeostasis: an emerging hallmark of cancer. 2025;(May). p. 1-3. doi:10.1097/ot9.0000000000000087
Ha JH, Prela O, Carpizo DR, Loh SN. p53 and Zinc: A Malleable Relationship. Front Mol Biosci. 2022;9:895887. Published 2022 Apr 13. doi:10.3389/fmolb.2022.895887
Wang J, Zhao H, Xu Z, Cheng X. Zinc dysregulation in cancers and its potential as a therapeutic target Zinc signaling Regulation of zinc homeostasis. Published online 2020. p. 615. doi: 10.20892/j.issn.2095-3941.2020.0106
Qu Z, Liu Q, Kong X, Wang X, Wang Z, Wang J. et al. A Systematic Study on Zinc-Related Metabolism in Breast Cancer. Nutrients. 2023;15(7). p. 1703. Published 2023 Mar 31. doi:10.3390/nu15071703
Nimmanon T, Ziliotto S, Morris S, Flanagan L, Taylor KM. Phosphorylation of zinc channel ZIP7 drives MAPK, PI3K and mTOR growth and proliferation signalling. Metallomics. 2017;9(5). p. 471-481. doi:10.1039/c6mt00286b
Corti C, Batra-sharma H, Kelsten M, Shatsky RA, Garrido-castro AC, Gradishar WJ. Systemic Therapy in Breast Cancer. American Society of Clinical Oncology. 2024;44(3).
Loibl S, Andre F, Bachelot T, Bergh J, Burstein HJ, Cardodo MJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis. 2024;2. p. 35. doi: 10.1016/j.annonc.2023.11.016
Ashriati A, Sedana MP, Bintoro UY, Diansyah MN, Amrita PNA, Savitri M, et al. Manajemen Kanker Payudara. Divisi Hematologi dan Onkologi, Departemen Penyakit Dalam, Fakultas Kedokteran Unair. Surabaya. 2019. p. 1-30
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28). p. 4414-4422. doi:10.1200/JCO.2007.10.6823
Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5). p. 320-327. doi:10.1016/s0960-9776(03)00106-1
Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkret C, et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. 2015;(December 2014). p.1185-1201. doi:10.1038/modpathol.2015.74
Allison KH, Ellis IO, Penault-Llorca F, Salomon AV, Schnitt S, Masuda S, et al. Invasive breast carcinoma: Of No Special Type. In: WHO Classification of Tumour Editorial Board. Breast tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed.; vol. 2). https://publications.iarc.fr/581
Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang AS, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021;39(13). p. 1485. doi:10.1200/JCO.20.03399
Guide HR. Invasive Carcinoma of the Breast in the Setting of Neoadjuvant Therapy Histopathology Reporting Guide.; 2022.
Dahlan MS. Statistik untuk Kedokteran dan Kesehatan. Epidemiologi Indonesia. 2020. p. 164
Holm J, Yu NY lin, Johansson A, Ploner A, Lindstro LS, Czene K, et al. Concordance of Immunohistochemistry Based and Gene Expression Based Subtyping in Breast Cancer. JNCI Cancer Spectrum. 2020;5(September):9. doi:10.1093/jncics/pkaa087
Kurnianingrum LL and Tjahjadi H. Profil Klinikopatologik Karsinoma Payudara Invasif Metastasis Jauh di Departemen Patologi Anatomik FKUI / RSCM Tahun 2019 Clinicopathological Profile of Invasive Breast Cancer with Distant Metastases in Anatomical Pathology Department FKUI / RSCM 2019. 2022;31(1):360.
Suanjaya MA, Utami S. Jurnal Aisyah : Jurnal Ilmu Kesehatan Prevalence and Characteristics of Breast Cancer Patients in Mataram City for the 2015-2020 Period. 2021;6(2):403. doi:10.30604/jika.v6i2.958
Cavelier E and Rogan E. Estrogen Carcinogenesis in Breast Cancer. Published online 2006:270-282.
Yager JD and Davidson NE. Estrogen Carcinogenesis in Breast Cancer. Published online 2006:270-282.
Nelson HD, Zakher B, Cantor A, Kerlikowske K, Van Ravesteyn NT, Trentham- A, et al. NIH Public Access. 2013;156(9):635-648. doi: 10.1059/0003-4819-156-9-201205010-00006.Risk
Setyawati Y, Rahmawati Y, Widodo I, Ghozali A, Purnomosari D. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph. 2018.p.1265. doi:10.22034/APJCP.2018.19.5.1263
Utomo HS, Gede D, Suprabawati A, Ali I. The relationship between residual cancer burden and disease-free survival in locally advanced post-neoadjuvant chemotherapy breast cancer at Dr. Soetomo General Hospital, Surabaya. 2024;13(2):925 doi:10.15562/bmj.v13i2.5050
Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Published online 2020:25-41. doi:10.32074/1591-951X-1-20
Rakha EA, Reis-filho JS, Baehner F, Dabbs DJ, Eusebi V, Fox Sb, et al. Breast cancer prognostic classifi cation in the molecular era: the role of histological grade. Published online 2010.
Rahmanti FA, Sandhika W, Tjandra L. Pathological and molecular parameters show no signoficant association with residual Cancer Burden, Pathological ang Molecular Parameters. Folia Medica Indonesiana. 2025:61(2).p.225-231.
Narciso E, Valente A, Bergman A, Bello MA, Thuler LCS. Prognostic Performance of the Residual Cancer Burden Index With Respect to Molecular Breast Cancer Subtypes. Eur J Breast Health. 2025;21(4):307-325. doi: 10.4274/ejbh.galenos.2025.2025-5-6
Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, et al. Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Is Response Similar to Typical ER-Positive or ER-Negative Disease? AJCP. Published online 2018:35. doi:10.1093/AJCP/AQY028
Ross DS, Pareja F. Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations. 2022;14(3):455-7. doi: 10.1016/j.path.2021.05.009.Molecular
Irmaya D, Hernowo BS, Dewayani BM, Medicine F, Padjadjaran U. Relationship between Histopathology Grading (Nottingham System) and Expression of HER2 / Subtype Luminal B in Breast Carcinoma with Lymph Node Metastases. 2025;34(3):983. doi:10.55816/mpi.v34i3.650
Takahashi H, Oshi M, Asaoka M, Yan L, Takabe K. HHS Public Access. 2021;27(11):4475-4485. doi: 10.1245/s10434-020-08608-1.Molecular
Osborne A, Adnani QES, Ahinkorah BO. Breast cancer incidence in Indonesia: a sex-disaggregated analysis using WHO health equity assessment toolkit data. BMC Cancer. 2025;25(1). p. 3-4. Published 2025 Jun 2. doi:10.1186/s12885-025-14332-4
Nindito RA, Isnaeni E, Fauziah N, Anugraheni CY. Profil dan Karakteristik Pasien Kanker Payudara di RSUP dr. Soeradji Tirtonegoro Klaten. 2025;2(2):110-11.
Luen SJ, Salgado R, Dieci M V, Vingiani A, Curigliano, G, Gaould RE, et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy Original article. 2019;30(2):236-242. doi:10.1093/annonc/mdy547
Chew H and Traina TA Invasive Carcinoma of the Breast in the Setting of Neoadjuvant Therapy Histopathology Reporting Guide In: ASCO SEP 2025. Lacy J (editors).2025. p.18.
Ziliotto S, Gee JMW, Ellis IO, Green AR, Finlay P, Gobatto A, et al. Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. Metallomics. 2019;11. p. 1579-1592. doi:10.1039/C9MT00136K
Jones S, Farr G, Nimmanon T, Ziliotto S, Gee JMW, Taylor KM, et al. The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer. Explor Target Antitumor Ther. 2022;3(2). p. 224-239. doi:10.37349/etat.2022.00080
Nimmanon T, Ziliotto S, Morris S, Flanagan L, Taylor KM. Phosphorylation of zinc channel ZIP7 drives MAPK, PI3K and mTOR growth and proliferation signalling. Metallomics. 2017;9(5). p. 471-481. doi:10.1039/c6mt00286b
Marvalim C, Datta A, Lee SC. Theranostics Role of p53 in breast cancer progression: An insight into p53 targeted therapy. 2023;13(4). doi:10.7150/thno.81847
Alamoodi M. Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review. 2024;20(1):8-14. doi: 10.4274/ejbh.galenos.2023.2023-11-2
Copyright (c) 2026 Winda Hasibuan, Betty, Lidya Imelda Laksmi, Jessy Chrestella, Devi Nafilah Yuzar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
